Travere Therapeutics
TVTX
169 hedge funds and large institutions have $737M invested in Travere Therapeutics in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 66 increasing their positions, 49 reducing their positions, and 34 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 49
3% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 34
0% more funds holding
Funds holding: 169 → 169 (0)
1.07% less ownership
Funds ownership: 111% → 109.93% (-1.1%)
32% less call options, than puts
Call options by funds: $14M | Put options by funds: $20.6M
42% less capital invested
Capital invested by funds: $1.27B → $737M (-$536M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$38.5M |
| 2 |
VA
VR Adviser
New York
|
+$37M |
| 3 |
Morgan Stanley
New York
|
+$20.3M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$18.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$97.9M |
| 2 |
O
OrbiMed
New York
|
-$32.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25M |
| 4 |
State Street
Boston,
Massachusetts
|
-$18.9M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.9M |
TVTX Hedge Fund Activity: Q3 2023 in Review
169 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2023, worth a combined $737M — down 42% from $1.27B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TVTX positions and 34 closed out — a net gain of 1 holder — while 66 added to existing stakes and 49 trimmed.
The largest buyer was Millennium Management, adding an estimated $38.5M. The largest seller was Janus Henderson Group, cutting an estimated $97.9M.
- 169 institutional investors held Travere Therapeutics (TVTX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $737M of Travere Therapeutics stock for Q3 2023, down 42% quarter-over-quarter.
- 35 funds opened new Travere Therapeutics positions in Q3 2023 and 34 closed out, a net change of +1 holder.
- The largest Travere Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $38.5M added.
- The largest Travere Therapeutics seller in Q3 2023 was Janus Henderson Group, an estimated $97.9M sold.
Based on aggregated 13F filings for Q3 2023.